Altor BioScience and Florida Biologix will collaborate in the development of  ALT-803, an interleukin-15 (IL-15)-based immunotherapeutic, to the clinic as a novel cancer therapy. ALT-803, a proprietary IL-15 super agonist/IL-15Rα-Fc fusion complex, has demonstrated anti-tumor activities in various preclinical cancer models and could potentially make a life-changing difference for patients with solid and hematological tumors, according to a joint statement. Florida Biologix will manufacture ALT-...